Related Experiment Videos
Pneumococcal vaccines: history, current status, and future directions
J C Butler1, E D Shapiro, G M Carlone
1Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
The American Journal of Medicine
|August 18, 1999
Summary
Preventing pneumococcal infections is crucial. Vaccines like the pneumococcal polysaccharide vaccine are recommended for high-risk groups, while new conjugate vaccines show promise for infants.
Area of Science:
- Immunology
- Infectious Diseases
- Vaccinology
Background:
- Streptococcus pneumoniae causes pneumonia and meningitis, remaining a major cause of illness and death globally.
- Antimicrobials have reduced fatality, but prevention through vaccination is key for high-risk populations.
Observation:
- Pneumococcal polysaccharide vaccines are effective in adults and immunocompetent children but not infants.
- Conjugating polysaccharides to carrier proteins enhances infant immunogenicity, with conjugate vaccines in efficacy trials.
- The efficacy of pneumococcal conjugate vaccines in adults requires further determination.
Findings:
- Pneumococcal polysaccharide vaccines are safe and effective for specific populations.
- Pneumococcal conjugate vaccines demonstrate improved immune responses in infants.
- Novel vaccine strategies targeting pneumococcal proteins and DNA are under investigation.
Implications:
- Optimizing pneumococcal polysaccharide vaccine use and developing new vaccines are essential.
- The rise of drug-resistant Streptococcus pneumoniae underscores the need for effective vaccination strategies.
- Future vaccines may offer complementary or alternative methods for preventing pneumococcal disease.